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Single cell resolution in vivo 
imaging of DNA damage following 
PARP inhibition
Katherine S. Yang1, Rainer H. Kohler1, Matthieu Landon1, 2, Randy Giedt1 & 
Ralph Weissleder1, 2
Targeting DNA repair pathways is a powerful strategy to treat cancers. To gauge efficacy in vivo, 
typical response markers include late stage effects such as tumor shrinkage, progression free 
survival, or invasive repeat biopsies. These approaches are often difficult to answer critical questions 
such as how a given drug affects single cell populations as a function of dose and time, distance 
from microvessels or how drug concentration (pharmacokinetics) correlates with DNA damage 
(pharmacodynamics). Here, we established a single-cell in vivo pharmacodynamic imaging read-out 
based on a truncated 53BP1 double-strand break reporter to determine whether or not poly(ADP-
ribose) polymerase (PARP) inhibitor treatment leads to accumulation of DNA damage. Using this 
reporter, we show that not all PARP inhibitor treated tumors incur an increase in DNA damage. The 
method provides a framework for single cell analysis of cancer therapeutics in vivo.
Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme that utilizes 
nicotinamide-adenine-dinucleotide (NAD+) to catalyze the addition of poly(ADP-ribose) (PAR) moieties 
onto target proteins1,2. These bulky, negatively charged PAR polymers affect numerous cellular processes, 
most notably by changing the localization and activity of signaling proteins3–5. PARP1 promotes DNA 
repair by undergoing a conformational change in response to single-strand and double-strand DNA 
breaks6–8. PARylation by PARP1 then leads to the recruitment of early DNA damage response factors, 
such as XRCC1, among many others9–15. Small molecule PARP inhibitors were originally developed 
for combined use with DNA damaging agents upon discovery that PARP1 is activated following either 
ionizing radiation or treatment with DNA-methylating agents4,8,16. In addition, the synthetic lethal rela-
tionship between PARP1 and BRCA has been exploited in several clinical trials4.
Most research on the mechanism of action and failure of PARP inhibitors has been limited to cell 
culture or traditional pharmacodynamic (PD) assays. These PD assays include measurements on tissue 
samples and traditional pharmacodynamic measurements of tumor volume following repeated inhibitor 
treatment in mice bearing BRCA wild-type or BRCA mutant tumors17–19. While these approaches are 
important towards developing more efficient PARP inhibitors, they often do not allow one to study effects 
at the single cell level in vivo. For example, there are a number of questions related to the mechanism 
of in vivo action (PD) such as: is the mechanism of action the same for every cell within the tumor or 
is there heterogeneity? Are there differences in response mechanisms within tumor classes (i.e. different 
models of ovarian cancer)? Do host cells impact efficacy? Which combination therapies work synergis-
tically (mechanistically within cells and between tumor and host cells)?
A critical aspect in understanding drug action in vivo are robust response markers which yield suf-
ficiently high signal-to-noise to be imaged in real time and which can be imaged in semiautomated 
fashion. Here we created a double-strand break (DSB) DNA damage reporter based on truncated 53BP120 
and using this approach, we measured the single-cell pharmacodynamics of olaparib in different xen-
ografts of human tumor-derived ovarian, breast, and Ewing’s sarcoma cancers21 (Fig.  1a). Our results 
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surprisingly show that i) DNA damage can be measured in vivo, ii) that, in the case of olaparib, in vitro 
measurements do not predict in vivo effects and iii) that there is no clear relationship between BRCA1 
status and sensitivity to the PARP inhibitor olaparib, at least in the studied xenografts of ovarian, breast 
and Ewing’s sarcoma tumors. The studies described here provide a framework for testing the single-cell 
pharmacodynamics of other DNA damaging agents.
Results
Development of a single-cell pharmacodynamic DNA damage reporter. To develop an in vivo 
single-cell pharmacodynamic assay to measure DSBs following olaparib treatment, we chose 53BP1 as 
Figure 1. Single-cell pharmacodynamic imaging analysis of olaparib efficacy. (a) Image stacks from 
53BP1trunc-Apple/H2B-GFP in vivo imaging experiments were analyzed using MATLAB to determine the 
number of foci on a per nucleus basis. Individual non-overlapping stacks were selected from a region of 
tumor imaging for analysis (a, left). Nuclei of interest were identified manually (a, center, red squares) and 
then the number of foci per nucleus were counted (a, right). The resulting number of foci per nucleus were 
plotted on a single-cell basis to determine if olaparib treatment caused an increase in the number of 53BP1 
foci. Scale bar = 20 μM. (b) Synthetic lethality in the context of PARPi and BRCA mutation. Treatment with 
PARP inhibitors leads to a block in the base excision repair pathway (BER-), which results in accumulation 
of single-strand DNA breaks. During cell division, these breaks accumulate as double-strand DNA breaks. 
One of the proteins that accumulates at sites of double-strand breaks is 53BP1 (red foci). In BRCA wild-type 
cells (homologous recombination positive, HR+), the double-strand breaks are repaired and the cell remains 
viable. However, in BRCA mutant cells (BRCA-), homologous recombination is blocked (HR-), which leads 
to sustained 53BP1 accumulation, unrepaired DNA damage, and eventual cell death. (c) Schematic of the 
53BP1trunc-Apple (amino acids 1220–1711)20 reporter for in vivo single-cell pharmacodynamics. (d) Example 
of PARPi (olaparib) induced increase in 53BP1 foci in an ovarian cancer cell line (OVCAR429) after 24 hrs 
of 100 μM olaparib. Scale bar = 20 μM.
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a DSB reporter, which has previously been used to measure DNA damage in live cells20,22–26(Fig.  1b). 
Specifically, we fused a truncated portion of 53BP1 (amino acids 1220-1711) to Apple fluorescent protein 
(53BP1trunc-Apple)20 (Fig. 1c). Apple fluorescent protein was used for in vivo imaging due to its increased 
brightness over mCherry, which is critical for successful imaging in live tissue. The truncated version 
of 53BP1 retains its ability to bind to sites of DSBs, but lacks the known functional domains of 53BP120 
(Fig.  1d). Moreover, we show that 53BP1trunc-Apple localizes to sites of double-strand breaks with an 
antibody targeting the canonical marker of double-strand breaks, γH2A.X (Supplementary Fig. S1).
Relationship between BRCA1 status and PARP expression. We chose a panel of breast and ovar-
ian cancer cell lines with either BRCA1 wild-type or mutant status, as well as several Ewing’s sarcoma cell 
lines that are BRCA1 wild-type, but had been shown to be sensitive to PARP inhibitors21 (Supplementary 
Table S1). Among these cell lines, we were first interested in whether or not BRCA1 status correlated 
with PARP1 expression and if PARP1 expression could therefore predict olaparib sensitivity. Western blot 
analysis revealed no obvious correlation between BRCA1 status and PARP expression (Supplementary 
Fig. S2). Some BRCA mutant cell lines had very low PARP1 expression (HCC1937), while others had 
high PARP1 expression (MDA-MB-436). Similarly, the wild-type cell lines ranged from low expressing 
(OVCAR429) to high expressing (A2780).
BRCA1 mutant cell lines are generally more sensitive to olaparib in vitro. We next compared 
cell viability following olaparib treatment to confirm the correlation between BRCA1 status and PARP 
inhibitor sensitivity. Cell lines were plated at low density and were treated with increasing concentrations 
of olaparib the following day. After six days treatment, viability was measured using a cell viability assay. 
As expected, the BRCA1 mutant cell lines generally exhibited increased sensitivity to olaparib compared 
to the wild-type cell lines (Table 1 and Supplementary Table S1, EC50 column; Supplementary Fig. S3), 
with the exception of the HCC1937 BRCA1−/− cell line, which has a relatively high EC50 of 3.7 μM. The 
Ewing’s sarcoma cell lines exhibited sensitivity comparable to that previously reported (MHH-ES1 is 
more sensitive than the SK-PN-DW cell line)21.
53BP1 foci generally increase more in BRCA1 mutant and Ewing’s sarcoma cell lines. To 
determine if DSB accumulation occurs in cell culture following olaparib treatment, all the cell lines listed 
in Table 1 and Supplementary Table S1 were transduced with lentivirus containing the 53BP1trunc-Apple 
pharmacodynamic reporter. Olaparib induction of DSBs was first measured in culture by single-cell imag-
ing. Each cell line was plated and the next day, increasing concentrations of olaparib were added. Cells 
were then imaged at 24 hrs (or serially in selected experiments) following olaparib treatment (Fig. 2). For 
each cell line, the percent increase in 53BP1trunc-Apple foci was then determined as a function of time 
and dose. Drug responses were compared by determining the half-maximal pharmacodynamic response 
(PD50; percent increase in foci/nucleus) as a function of olaparib dose. Interestingly, the PD50 values - a 
measure of DSB effect - do not always correlate with the EC50 values, a measure of cell kill (Table  1, 
Supplementary Table S1, and Fig. 3A). For example, the A2780 ovarian cancer cell line had a high EC50 
value, but a very low PD50 value. This is likely the case because the DSBs that appear after 24 hrs of olap-
arib treatment are later repaired rather than the cells undergoing cell death (Supplementary Table S1).
In contrast to what the synthetic lethal model would predict for PARP inhibitors, the HCC1937 
BRCA1−/− cell line had a high EC50 and PD50 value. We thus asked if this BRCA1 mutant cell line is either 
insensitive to olaparib or whether it simply required longer drug incubation to observe an increase in 
DSBs? To address this question, 53BP1trunc-Apple foci formation was imaged and analyzed again at 48 hrs 
PD50 (μM) in vitro






Breast MDA-MB-436 −/− WT Hi 0.032 0.15 0.19 0.05 3.9
HCC1937 −/− WT Low 3.7 0.6 0.7 0.09 1.7
Ewing’s MHH-ES1 WT WT Hi 0.16 0.02 ND ND 2.5
Table 1.  Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma 
cell lines. Wild-type or BRCA mutant status is shown for each cell line (compiled from the COSMIC 
database and literature). Relative PARP expression is qualitatively compared from the Western blot in 
Supplementary Fig. S2. The EC50 value from viability assays in cell culture is also shown. The PD50 value 
(half-maximal pharmacodynamic response) was determined from imaging and quantifying the increase 
in foci formation following olaparib treatment and fitting the resulting curve to a dose response using 
GraphPad (Prism) (ND = not determined). The in vivo maximum fold change was determined by comparing 
the number of foci from pre-treatment and after daily IP injections of olaparib.
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and 6 days after olaparib treatment (this was done for both the HCC1937 and MDA-MB-436 cell lines). 
Not surprisingly, the PD50 values remain the same after 48 hrs of olaparib treatment (Table 1). However, 
after 6 days olaparib treatment, the PD50 values decreased 3-fold for the MDA-MB-436 cells and 7-fold 
for the HCC1937 cells (Table 1). The increase in DSBs (and resulting decrease in PD50) after 6 days of 
olaparib treatment is consistent with a need for the cells to go through several rounds of cell division to 
accumulate sufficient numbers of DSBs, particularly at lower concentrations of olaparib. However, for 
the BRCA1−/− HCC1937 cell line, the increase in DSBs at 6 days (PD50) still did not translate to a lower 
EC50 value. It is possible that in this cell line, the additional time required to accumulate DSBs translates 
into additional time required to observe a decrease in cell viability. Another possibility is that DNA 
repair pathways in the HCC1937 cell line still function at levels sufficient to repair the damaged DNA. 
In general, the data in Table 1 and Supplementary Table S1 show that the BRCA mutant cell lines and 
the expected Ewing’s sarcoma cell lines were sensitive to olaparib.
Development of an in vivo model system to image 53BP1 DNA damage. Ultimately our inter-
est was in measuring DSB accumulation in vivo. As an initial validation of the 53BP1trunc-Apple reporter 
in vivo, we analyzed the number of foci per nucleus in HT1080 xenografts before and after vehicle 
or cisplatin (a robust DNA damaging agent) treatment. Supplementary Figure S4 shows that cisplatin 
Figure 2. Single-cell pharmacodynamic imaging in cell culture. The indicated cell lines from ovarian, 
breast, or Ewing’s sarcoma were treated with increasing concentrations of olaparib for 24 hrs, at which point 
the cells were imaged for 53BP1trunc-Apple foci (left). The percentage of cells with greater than the baseline 
(DMSO control) number of foci was plotted versus olaparib concentration and fit to a sigmoidal dose 
response curve using Prism (GraphPad) to obtain PD50 values (Table 1 and Supplementary Table S1). Data 
are representative of at least two independent experiments. Scale bar = 20 μM.
www.nature.com/scientificreports/
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treatment resulted in a statistically significant increase in the mean number of foci per nucleus, indicat-
ing the 53BP1trunc-Apple reporter functions as expected in vivo.
To examine the effects of olaparib in vivo we established xenograft tumors of cells stably expressing 
the 53BP1trunc-Apple reporter and imaged these tumors at high spatial resolution to resolve the nuclear 
phenotype of DSB. We focused on three representative models in which serial measurements were carried 
out at different doses (50 or 100 mg/kg olaparib): MDA-MB-436 (breast cancer), HCC1937 (breast can-
cer), and MHH-ES1 (Ewing’s sarcoma). Tumors were imaged daily for the first week and then every few 
days thereafter until imaging was no longer feasible. A MATLAB script was utilized for semi-automated 
analysis of the single cell data (Fig.  1A). Nuclei regions of interest were identified manually and then 
the number of foci per nucleus was counted for 200–600 single cells from each tumor for each day of 
imaging (Fig. 4).
Ewing’s sarcoma MHH-ES1 tumors exhibit more DNA damage following olaparib treat-
ment. Figure 4 summarizes a set of experiments in the MHH-ES1 model. Examples of the regions of 
interest for the cells that were imaged each day is shown. Analysis of the fold change in number of foci 
per nucleus from pre-treatment (day 0) showed a gradual increase with a maximal fold change by day 
8 of 100 mg/kg olaparib treatment (Fig. 4 and 5 and Table 1). Importantly, a tumor treated with vehicle 
(DMSO alone in DMAC/Solutol and PBS) did not show an increase in the average number of foci over 
time (Fig. 4B and Fig. 5). Interestingly, 50 mg/kg olaparib did not show any effects, but the higher dose 
of 100 mg/kg did (Fig. 6A and B). These data suggest that there is a dose dependence in the appearance 
of a pharmacodynamic DSB response. The MHH-ES1 cells in this particular tumor were also transfected 
with an H2B-GFP reporter that allows visualization of dividing cells, as well as cells that have recently 
undergone apoptosis27. Both of these events are crucial to the efficacy of olaparib treatment. Cell divi-
sion indicates the ability of cells to accumulate double-strand DNA damage from the olaparib-induced 
single-strand DNA damage. This phenomenon was observed in the MHH-ES1 cell line following olap-
arib treatment (Fig. 5). Using the H2B-GFP reporter, we also observed the ultimate apoptotic effects of 
olaparib (Fig. 5).
At the end point of imaging, MHH-ES1 tumors treated with 100 mg/kg olaparib were isolated and the 
cells were dissociated and re-grown in vitro. Using these cell lines established from tumors treated with 
olaparib, we repeated the viability assays described earlier. Compared to the cell lines before growth in 
vivo, the tumor cell lines displayed a 6-fold increase in EC50 (Fig. 6C). These data suggest that growth 
and exposure to olaparib in vivo fundamentally alters the tumor cells, making them less sensitive to the 
inhibitor.
MDA-MB-436 tumors show increased 53BP1 foci after olaparib treatment. Similar analysis as 
above for Ewing’s sarcoma was also done for MDA-MB-436 BRCA1−/− tumors expressing the imaging 
reporter (Fig. 7). An increase in the number of foci per nucleus was observed by 21 days following daily 
olaparib treatment (Fig.  7 and Table  1). Both doses (50 and 100 mg/kg) of olaparib ultimately led to 
~4-fold increase in the number of foci per nucleus. Olaparib-treated tumors were also irradiated with 
10 gray at the experimental end point to demonstrate that the 53BP1trunc-Apple reporter was indeed 
functional, which was confirmed (Fig. 7A, IR).
HCC1937 BRCA mutant tumors do not undergo increased 53BP1 foci in vivo after olaparib 
treatment. Finally, two different HCC1937 BRCA1−/− tumors were studied, each dosed daily with 
Figure 3. Correlation between pharmacodynamic parameters. (a) The half-maximal pharmacodynamic 
response (PD50) from in vitro experiments was plotted versus the EC50 value from viability assays for the 
cell lines listed in Supplementary Table S1. (b) The maximum fold change in foci formation in vivo (x-axis) 
is plotted versus the half-maximal pharmacodynamic response (PD50, blue) or versus the EC50 (red) from 
viability assays.
www.nature.com/scientificreports/
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100 mg/kg olaparib (Fig. 8A). While the maximal fold change was slightly higher in cell culture for this 
line (~2.5-fold at 6 days olaparib treatment, data not shown), the single-cell tumor imaging showed 
essentially no fold change from pre-treatment over the 11 day treatment period. This lack of change is 
also consistent with the viability data for this cell line, which showed relatively poor sensitivity to olap-
arib (Table 1). The lack of a pharmacodynamic response from the HCC1937 cell line in vivo is not due 
to poor pharmacokinetics of olaparib on the tumor. Using a previously established olaparib-BODIPY FL 
companion imaging drug28 and an HCC1937 53BP1trunc-Apple tumor, we observed uptake of the drug 
in all the tumor cell nuclei (Fig. 8B). This suggests that not all BRCA1 mutant tumors undergo a DNA 
damage response following olaparib treatment. However, it is possible that the BRCA1 mutant tumor 
would shrink and respond to olaparib, perhaps through a different and yet unrealized mechanism.
Discussion
The synthetic lethal relationship between PARP1 and BRCA has been the firm basis of designing recent 
clinical trials4. These trials showed promising results early on in BRCA deficient breast and ovarian can-
cer with the inhibitor olaparib29. Based on these early advancements, the target patient population was 
expanded to include those that displayed BRCAness, where BRCA1 and BRCA2 are intact, but other HR 
defects exist. Iniparib showed early promise in a phase 2 trial in triple-negative breast cancer (TNBC) 
patients that had a BRCAness signature30. However, in a phase 3 trial, iniparib failed in the same patient 
population and at the same time olaparib showed no overall benefit in TNBC patients or overall survival 
in ovarian cancer patients31–33. While PARP inhibitor trials were temporarily halted, more recent studies 
show that iniparib was not a true PARP inhibitor34,35. Moreover, olaparib was reevaluated based on BRCA 
Figure 4. In vivo single-cell pharmacodynamic analysis of 53BP1 double-strand break formation 
following olaparib treatment in Ewing’s sarcoma tumors. (a) Representative images of single cells from an 
MHH-ES1 tumor prior to treatment and after eight days of 100 mg/kg Olaparib. Images are separated into 
≤2 foci per nucleus (2 is the average number of foci per nucleus pre-treatment) and >2 foci per nucleus. 
Percentage values at the bottom represent the percentage of the total number of nuclei that fall into either 
of these groups. (b and c) Single cell data for a nu/nu mouse with a Ewing’s sarcoma tumor xenograft 
(MHH-ES1 cells) that was treated for the duration of imaging with vehicle alone (b, 10% DMAC/Solutol in 
PBS) or with 100 mg/kg Olaparib (c). Note for b and c, each point represents the number of foci in a single 
nucleus, with 200–600 single cells analyzed for each day of imaging. The black line represents the mean 
number of foci per nucleus for each day of imaging.
www.nature.com/scientificreports/
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status, with results showing overall survival in patients with defective BRCA protein. Despite the sound 
scientific rationale36–38, extensive in vitro assay and preclinical studies17–19,39–41, the clinical results were 
mixed29–33,42–44. Furthermore, previous studies using fluorescent olaparib had shown that the drug clearly 
distributes throughout tumors and has a unique nuclear phenotype of accumulation in vivo28. Finally, 
mathematical modeling had shown that the human doses would clearly result in efficacy in cancer cells28. 
So, how can these discrepant results be explained?
In order to gain insight into the pharmacologic actions of PARP inhibitors, we have created tool sets 
to measure pharmacokinetics28 and now also pharmacodynamics at the single cell level in vivo and in 
real-time. The latter was accomplished by creating a sufficiently bright fluorescent 53BP1 reporter for 
confocal/multiphoton in vivo imaging. This reporter shows a remarkable phenotype (Fig. 1D) and allows 
one to derive quantitative measures of drug efficacy (EC50: concentration at which half of the cells die, 
PD50: concentration at which half of the cells show DNA damage in vitro, in vivo: maximum fold increase 
in DNA damage relative to pre-treatment). Our data in cell culture shows that the 53BP1trunc-Apple 
reporter generally agrees with the viability data for each cell line, with the major exception being the 
HCC1937 cell line. This line is BRCA1 mutant and has a low PD50 value after 6 days of olaparib treat-
ment, indicating a strong increase in DSBs, but a high EC50 value over the same time frame, which 
indicates the cells do not die readily in response to olaparib. Perhaps this is owing to the relatively low 
expression of PARP1 in these cells compared to the other more responsive cell lines.
In vivo we show with three different tumor models, two of which are BRCA1 mutant, that there is a 
difference in the number of DSBs observed depending on the daily dose of olaparib. For one of the cell 
lines (MHH-ES1), a lower dose of olaparib (50 mg/kg) did not increase the number of DSBs. However, 
with a dose of 100 mg/kg a significant number of DSBs were observed. Surprisingly, the MDA-MB-436 
cell line showed the greatest increase in the number of 53BP1trunc-Apple foci, even at the 50 mg/kg olap-
arib dose. This is in contrast to the cell culture data, which suggested that while the MDA-MB-436 
cell line displayed high sensitivity to olaparib in a viability assay, there was only a moderate change in 
53BP1trunc-Apple foci. Similarly, the HCC1937 BRCA1 mutant cell line showed little change in the num-
ber of foci in vivo, even at the higher 100 mg/kg daily dose of olaparib.
With certain caveats, the experiments of this study suggest two main conclusions: i) often there is 
no clear relationship between BRCA1 status and sensitivity to olaparib and ii) in vitro cell culture data 
do not predict in vivo efficacy for the PARP inhibitor studied here. While the MDA-MB-436 cell line is 
sensitive in vivo, the HCC1937 cell line is not, despite both lines being BRCA1−/−. This suggests that if 
Figure 5. Serial in vivo imaging of a nu/nu mouse with a MHH-ES1 Ewing’s sarcoma tumor expressing 
the 53BP1trunc-Apple (green) and H2B-GFP (red) reporter. The mouse was dosed daily with 100 mg/
kg olaparib by IP injection (blue curve, n = 3) or vehicle (10% DMAC/Solutol in PBS, n = 1). Days 8–17 
indicate pooled data from mice imaged on different days after olaparib treatment. Dividing cells (arrow) 
and apoptotic cells (arrowhead) were observed using the H2B-GFP (red) reporter. Error bars represent the 
standard error of the mean. Scale bar = 20 μm (inset magnified 1.7-fold).
www.nature.com/scientificreports/
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HCC1937 tumors still decrease in size, it is likely independent of the synthetic lethal concept. PARP1 
has a plethora of other functions in the cell ranging from promotion of transcription to chromatin 
modification to changes in signaling pathways. Modification of any of these pathways/proteins through 
PARP1 inhibition could in theory affect tumor growth. Recent studies demonstrate that olaparib induces 
a G2 phase arrest-like state, resulting in upregulation of p53 and p2145–47. Furthermore, these studies 
suggest that olaparib is most effective in cell lines with mutated p53. Here, the cell lines studied in vivo 
all have mutant p53 status48 (and canSAR database). Interestingly, the HCC1937 cell line has strong 
basal expression of p21, while the MDA-MB-436 and MHH-ES1 cell lines do not (Supplementary Fig. 
S5). Thus, it is possible that the HCC1937 cell line arrests during the cell cycle and does not proliferate 
at the same rate as the MDA-MB-436 and MHH-ES1 cell lines in vivo. Replication is essential to PARP 
inhibitor function in the context of synthetic lethality (Fig. 1B), suggesting that cell lines that may pro-
liferate more slowly (such as HCC1937) may be less sensitive to olaparib. We also show that the Ewing’s 
sarcoma tumor is sensitive to olaparib in vivo, consistent with previous cell culture data21. These data also 
Figure 6. Effect of olaparib concentration on MHH-ES1 Ewing’s sarcoma tumors expressing the 
53BP1trunc-Apple reporter in nu/nu mice. (a) Representative single-cell data showing the number of foci 
on a per nucleus basis for a mouse treated daily with 50 mg/kg olaparib (IP). Each point indicates the 
number of foci in a single nucleus, with black lines on each day representing the mean number of foci. (b) 
Comparison of the fold change in the number of foci for the 50 mg/kg (red, n = 2) and 100 mg/kg (blue, 
n = 3, same data as in Fig. 5 for comparison) olaparib doses (relative to day 0 prior to olaparib treatment). 
Error bars represent the standard error of the mean. (c) Comparison of cell viability following treatment 
with increasing concentrations of olaparib for 6 days in MHH-ES1 cells grown in culture alone (red) or 
grown in vivo and then dissociated and re-grown in cell culture at the endpoint of olaparib treatment/
imaging (blue). Data were fit to a sigmoidal dose-response curve using Prism (GraphPad), with error bars 
representing the standard error of the mean.
Figure 7. In vivo quantification of the number of foci per nucleus in MDA-MB-436 cells expressing 
the 53BP1trunc-Apple reporter in a nu/nu mouse. (a) Representative single cell data from a mouse treated 
with daily IP injections of 50 mg/kg olaparib. Each point represents an individual nucleus in vivo, with the 
y-value equal to the number of foci in that nucleus. 200–600 cells were analyzed each day following olaparib 
treatment and the black bar represents the average number of foci on each day. (b) Comparison of the fold 
change in the average number of foci per nucleus for daily IP injection of 50 mg/kg (n = 1) versus 100 mg/kg 
olaparib (n = 1).
www.nature.com/scientificreports/
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highlight the importance of in vivo measurements of single-cell pharmacodynamics. The cell culture data 
would predict that all the cell lines we tested in vivo would show an increase in DSBs following olaparib 
treatment, which is clearly not the case. We believe that the methodology we have established here to 
measure DSBs will be applicable not only to PARP inhibitors, but to other agents that also induce DSBs. 
Similar types of reporters could also be established for other cell processes so that one can gain a more 
complete view of drug action in vivo.
Materials and Methods
Cell lines and growth conditions. The UWB1.289, MDA-MB-436, MDA-MB-231, and SK-PN-DW 
cell lines were purchased from the American Type Culture Collection (ATCC). A2780 and OVCAR429 
cell lines were kind gifts from Dr. Michael Birrer (Massachusetts General Hospital, Boston, MA). The 
HCC1937 cell line was a kind gift from Prof. Timothy Mitchison (Department of Systems Biology, 
Harvard Medical School, Boston, MA). The TC-252 cell line was a kind gift from Dr. Francis Hornicek 
(Massachusetts General Hospital, Boston, MA). MHH-ES1 cells were purchased from CLS Cell Lines 
Service (order # 300136).
MDA-MB-436, MDA-MB-231, A2780, OVCAR429, MHH-ES1, and HCC1937 cells were maintained 
in RPMI supplemented with 10% fetal bovine serum, 100 IU penicillin, 100 μg/ml streptomycin, and 
L-glutamine. UWB1.289 cells were maintained in 50% RPMI, 50% MEGM (consisting of MEBM basal 
medium and SingleQuot aliquots, excluding gentamycin-amphotericin B; Lonza CC-3150), 3% fetal 
bovine serum, 100 IU penicillin, 100 μg/ml streptomycin, and L-glutamine. SK-PN-DW, TC-252, and 
HT1080 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 IU penicillin, 
Figure 8. In vivo quantification of the fold change in foci formation in HCC1937 53BP1trunc-Apple 
cells grown in nude mice. (a) The fold change in the number of foci was determined relative to day 0 of 
treatment with 100 mg/kg olaparib. Error bars represent the standard error of the mean for n = 2 mice. (b) 
Olaparib-Bodipy FL nuclear uptake in a nu/nu mouse with an HCC1937 tumor. The 53BP1trunc-Apple 
reporter (red nuclei, left) was imaged 2 hrs after IV administration of olaparib-Bodipy FL (green, center). 
Images from the 53BP1trunc-Apple (red) channel and the olaparib-Bodipy FL (green) channel were overlaid 
(merge, right) to show that olaparib-Bodipy FL accumulates in all HCC1937 tumor cell nuclei. Scale 
bar = 20 μm.
www.nature.com/scientificreports/
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100 μg/ml streptomycin, and L-glutamine. Cells expressing 53BP1trunc-Apple were maintained in 3 μg/ml 
puromycin and cells co-expressing H2B-GFP were also maintained in 200 μg/ml G418.
Constructs. Truncated 53BP1 (amino acids 1220–171120) was PCR amplified from 53BP1-YFP (kind 
gift from Prof. Galit Lahav, Harvard Medical School, Boston, MA). The PCR product was cloned into 
the pLVX lentiviral vector (632562, Clontech) containing a C-terminal Apple fluorescent protein (27698, 
Addgene), using In-Fusion cloning (639645, Clontech) and the BsrGI and XbaI restriction enzyme sites 
on the pLVX vector. The 53BP1trunc-Apple insert was sequenced in its entirety.
The H2B-GFP reporter was created by replacing Apple fluorescent protein in pTag-H2B-Apple49 
(FP176, Evrogen) with pAcGFP1 (632492, Clontech). pTag-H2B-Apple was digested using the AgeI and 
NotI restriction enzymes, while pAcGFP1-HyG-C1 was digested using the AgeI and BspOMI restriction 
enzymes. pAcGFP1 was then ligated into the pTag-H2B vector and the resulting insert was sequenced 
in its entirety.
Transfection and lentiviral infection. Lentiviral particles of the 53BP1trunc-Apple reporter were 
produced in Lenti-X 293T cells (632180, Clontech) following the manufacturers’ instructions. Briefly, 
2 × 106 Lenti-X 293T cells were plated in a 10 cm dish. The following day, cells were transfected with the 
pLVX 53BP1trunc-Apple reporter using Xfect (631317, Clontech). After 6 hrs, the media was changed to 
remove transfection complexes. 48 hrs after transfection the media was collected and filtered through 
0.45 μm cellulose acetate. Viral particles were then concentrated using Lenti-X concentrator (631231, 
Clontech). Cells were plated at 50,000 cells per 12-well dish and the following day were transduced with 
53BP1trunc-Apple lentiviral particles in media containing 4–10 μg/ml polybrene (depending on the cell 
line). Media was exchanged after 24 hrs and cells were split into media containing 3 μg/ml puromycin 
for selection after 48 hrs. Reporter expression was confirmed by fluorescence microscopy and cells with 
uneven expression were sorted by flow cytometry.
For co-expression of H2B-GFP, cells were plated 24 hrs before transfection and the following day, 
the pTag H2B-GFP plasmid was transfected into cells using Lipofectamine 2000 (11668-027, Life 
Technologies). Transfected cells were split into media containing 500–1000 μg/ml G418. Cells positive 
for both 53BP1trunc-Apple and H2B-GFP were obtained by FACS or by isolating individual colonies after 
selection.
Western blot. Cells were grown to confluence, washed twice with ice-cold PBS and then lysed in 
radioimmunoprecipitation buffer (RIPA, 9806S, Cell Signaling Technology) containing HALT protease 
inhibitor cocktail (87786, Pierce). Lysates were transferred to microfuge tubes, passed through a 23 g 
syringe, and incubated five minutes on ice. Lysates were sonicated for 40 s and then centrifuged at 14,000 
× g for 15 min at 4 °C to remove cellular debris. Total protein was measured using the BCA assay (23227, 
Pierce) and equal protein was loaded on a 4–12% NuPAGE Bis-Tris gel (NP0322BOX, Life Technologies). 
Protein was then transferred to nitrocellulose and stained for total protein (for normalization) using the 
reversible protein stain kit for nitrocellulose membranes (24580, Pierce). Following staining and docu-
mentation, the stain was removed and the blot was blocked in SuperBlock T20 (TBS) (37536, Pierce), fol-
lowed by brief washing in TBS containing 0.1% Tween-20 (TBST). Blots were incubated overnight at 4 °C 
in PARP1 (9532, Cell Signaling Technology), p53 (2527, Cell Signaling Technology), or p21 (2947, Cell 
Signaling Technology) primary antibody diluted 1:1000 in 10% SuperBlock/TBST. Blots were washed 
three times, 5 min each, followed by a one hour incubation in HRP-conjugated secondary antibody. 
Following secondary incubation, cells were again washed three times, 5 min each in TBST followed by 
detection using SuperSignal West Pico chemiluminescent substrate (34077, Pierce). PARP1 expression 
was quantified by densitometry using ImageJ (NIH) and normalized using the total protein stain and 
densitometry of ~80 kDa band in each lane. PARP1 expression was quantified from two independent 
experiments, with error calculated as standard error of the mean.
PrestoBlue viability assay. Cells were plated at 1000 to 3000 cells per well (depending on the cell 
line) 24 hrs prior to addition of olaparib (S1060, Selleckchem). Increasing concentrations of olaparib (0 
to 100 μM) were added to each well for six day incubation. Cell viability was measured on the sixth day 
using the PrestoBlue cell viability reagent (A13261, Life Technologies) and a Tecan Safire2 plate reader 
in fluorescence mode (Männedorf, Switzerland). Data were plotted as percent viability versus olaparib 
concentration and the resulting curve was fit to a sigmoidal dose response equation using GraphPad 
(Prism). Error was calculated as standard error of the mean between triplicate measurements. Data are 
representative of at least two independent experiments.
Olaparib 53BP1trunc-Apple live cell imaging. Cells were plated at 2000 to 10,000 cells per well 
(depending on the number of days of olaparib treatment) in 96-well plates for microscopy (89626, iBidi). 
After 24 hrs, increasing concentrations of olaparib (0–100 μM) were added to the cells. Imaging was done 
on a DeltaVision (Applied Precision/GE Healthcare) microscope equipped with a 40X objective and a 
humidified environmental chamber 24 hrs after addition of olaparib (as well as 48 hrs and 6 days for 
select cell lines).
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For colocalization with γH2A.X, cells were fixed with 4% paraformaldehyde after treatment for 24 hrs 
with 100 μM olaparib or 1 μM etoposide or 1 hr with 10 μM cisplatin (followed by 24 hr recovery). Cells 
were permeabilized using 100% MeOH, washed with PBST (PBS plus 0.1% Tween-20), blocked with 
odyssey blocking buffer (Li-COR), and incubated overnight at 4 °C in primary γH2A.X (phospho S139, 
abcam, ab26350) antibody diluted 1:100 in odyssey blocking buffer. Cells were washed with PBST and 
incubated 1 hr at room temperature in AlexaFluor 647 goat anti-mouse secondary antibody (1:100, Life 
Technologies). Cells were then imaged using a DeltaVision microscope equipped with a 40X objective.
In vivo single-cell pharmacodynamic imaging. All animal experiments were carried out in accord-
ance with guidelines from the Institutional Subcommittee on Research Animal Care. Female nude mice 
(8–10 weeks old, Cox7, Massachusetts General Hospital) were implanted in the dorsal skinfold/subcuta-
neously with 2–4 × 106 cells that were suspended 1:1 in Hank’s balanced salt solution (HBSS) and Matrigel 
(356237, BD Biosciences). Tumors were allowed to grow (2 weeks to 2 months depending on the cell 
type) until they became vascularized and reached 1–2 mm in size. At this point, mice were surgically 
implanted with a dorsal skin fold window chamber. For the HT1080 experiments, window chambers 
and cells were implanted at the same time (without matrigel). Prior to olaparib treatment, mice were 
anesthetized with 2% isoflurane in 2 L/minute oxygen on a heated microscope stage. Day 0 images were 
collected from various regions of the tumor on an FluoView FV1000 confocal microscope (Olympus) 
equipped with a 20X water immersion objective. Mice were then treated daily by IP injection with 50 mg/
kg olaparib (80 mg/ml stock in DMSO diluted in PBS with 10% DMAC/Solutol) or on a cycle of 5 days 
dosing, 2 days rest with 100 mg/kg olaparib. Initially, image stacks were collected daily and then every 
few days during olaparib treatment. For the HT1080 experiments, Cisplatin was injected as a single IV 
dose of 9 mg cisplatin per kilogram (in 10% solutol in saline)
Olaparib-Bodipy FL imaging in a nude mouse with a HCC9137 53BP1trunc-Apple tumor was done as 
previously described28. Briefly, 75nmol (7.5 μl of 10 mM stock in DMSO) olaparib-Bodipy FL was diluted 
in 30 μl of a 1:1 dimethylacetamide (DMAC): solutol solution. PBS (112.5 μl) was then slowly added with 
sonication to obtain a final injection volume of 150 μl. Olaparib-Bodipy FL was injected via a tail vein 
catheter.
Live cell and in vivo pharmacodynamic reporter analysis. Live cell imaging data and maximum 
intensity projections of select stacks from in vivo imaging were analyzed in 2D. Briefly, an in house 
produced MATLAB code was constructed to assist with foci counting. In this program, single cells were 
manually selected. Base level noise for the selected area was automatically filtered via Otsu’s method for 
thresholding. Foci were then automatically detected via incorporation of an automated algorithm for 
detecting and filtering local intensity clusters50, freely available from the Danuser group51. Results were 
verified by eye in each case. The average baseline number of foci prior to olaparib treatment was deter-
mined and the fold increase in foci formation (relative to day 0) was calculated for each concentration 
of olaparib (in vitro) or dose of olaparib (in vivo). The MATLAB code used to aid in image analysis is 
available upon request.
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